Alternating versus sequential chemotherapy in small cell lung cancer. A randomized german multicenter trial

Cancer

Volumn 59, Issue 6, 1987, Pages 1072-1082

  Havemann, Klaus ^a   Wolf, Martin ^a   Holle, Rolf ^a   Gropp, Claus ^a   Drings, Peter ^a   Manke, Hans‐Georg ^a   Hans, Klaus ^a   Schroeder, Michael ^a   Heim, Manfred ^a   Victor, Norbert ^a   Georgii, Axel ^a   Thomas, Carlos ^a   Pflüger, Karl‐Heinz ^a   Bepler, Gerold ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; VINCRISTINE; VINDESINE;

ADVERSE DRUG REACTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HUMAN; INTOXICATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SURVIVAL; THERAPY; TOXICITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LOMUSTINE; LUNG NEOPLASMS; MALE; METHOTREXATE; PROGNOSIS; VINCRISTINE; VINDESINE;

EID: 0023129093     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19870315)59:6<1072::AID-CNCR2820590605>3.0.CO;2-W     Document Type: Article

References (43)

1. Cancer of the lung
2. The natural 5‐year course in bronchial carcinoma: Epidemiologic results
3. Alkylating agents in bronchogenic carcinoma
4. Small cell carcinoma of the lung: Combined chemotherapy and radiation
5. Small cell lung cancer: Complete remission and improved survival
6. Randomized trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiple agent chemotherapy and elective brain irradiation: A preliminary report
7. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung
8. Combined modality treatment of extensive small cell lung cancer: A Southwest Oncology Group Study
9. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung
10. VP16–213 in combination chemotherapy with chest irradiation for small cell lung cancer: A randomized trial of Piedmont Oncology Association
11. Etoposide (VP16) in treatment of lung cancer
12. Ifosfamide in the treatment of recurrent or disseminated lung cancer
13. Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma
14. Phase II study of vindesine in patients with small cell lung carcinoma
15. Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma
16. Cis‐dichloro‐diamineplatinum (II) and VP16‐213: An active induction regimen for small cell carcinoma of the lung
17. The combination of VP16‐213 and cisplatinum in the treatment of small cell carcinoma of the lung (Abstr)
18. Phase II study with cis‐dichlorodiammineplatinum (II) in small cell anaplastic carcinoma
19. Phase II trial of cisplatin in small cell carcinoma of the lung
20. Chemotherapy of advanced small cell anaplastic carcinoma: Superiority of a four‐drug combination to a three‐drug combination
21. Combined methotrexate and high‐dose vincristine chemotherapy with radiation therapy for small cell bronchogenic carcinoma
22. High‐dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma
23. Combination chemotherapy, radiotherapy, and BCG immunotherapy in limited small cell carcinoma of the lung
24. Chemotherapy of small cell carcinoma of lung: A randomized comparison of alternating and sequential combination chemotherapy programs
25. Cyclic non‐cross resistant combination chemotherapy (CT) for small cell lung cancer (SCLC) in remission (R): Fifty percent prolongation of remission duration without prolongation of survival and with enhanced toxicity (Abstr)
26. Combination chemotherapy for small cell carcinoma of the lung: Continuous versus alternating non‐cross‐resistant combinations
27. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small cell carcinoma of the lung: A phase III cancer and leukemia group B study
28. Canadian multicenter randomized trial comparing sequential (S) and alternating (A) administration of two non‐cross resistant chemotherapy combinations in patients with limited small cell carcinoma of the lung (SCLC) (Abstr)
29. Small cell carcinoma of the lung: Experience with a six‐drug regimen
30. POCC versus POCC/VAM therapy for small cell anaplastic (oat cell) lung cancer
31. Rationale for the use of alternating non‐cross‐resistant chemotherapy
32. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variant
33. Alterations in design while a clinical trial is in progress
34. A multiple testing procedure for clinical trials
35. Regression models and life tables
36. “Very limited” small cell lung cancer (SCLC): Results of a non‐surgical treatment (Abstr)
37. Long‐term survival in small cell carcinoma of the lung
38. Long‐term survival and toxicity in small cell lung cancer: Southwest Oncology Group Study